$LBPH
Longboard Pharmaceuticals Inc

2021 Q4 Form 10-Q Financial Statement

#000095017021003093 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.426M $2.262M $1.829M
YoY Change -69.45% 23.67%
% of Gross Profit
Research & Development $6.368M $4.100M $1.600M
YoY Change 193.46% 156.25%
% of Gross Profit
Depreciation & Amortization $1.000K
YoY Change
% of Gross Profit
Operating Expenses $8.794M $6.355M $2.550M
YoY Change -13.02% 149.22%
Operating Profit -$6.355M -$2.550M
YoY Change 149.22%
Interest Expense $24.00K $23.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$3.000K -$13.00K
YoY Change
Pretax Income -$8.773M -$6.345M -$4.291M
YoY Change -13.22% 47.87%
Income Tax
% Of Pretax Income
Net Earnings -$8.773M -$6.345M -$2.550M
YoY Change -13.22% 148.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.38
Diluted Earnings Per Share -$515.3K -$376.2K -$253.7K
COMMON SHARES
Basic Shares Outstanding 17.22M 17.22M
Diluted Shares Outstanding 16.87M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.7M $112.6M $200.0K
YoY Change 92.99% 56179.5%
Cash & Equivalents $66.35M $75.46M $217.0K
Short-Term Investments $40.38M $37.10M
Other Short-Term Assets $1.659M $2.740M $0.00
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $108.4M $115.3M $200.0K
YoY Change 95.77% 57549.5%
LONG-TERM ASSETS
Property, Plant & Equipment $14.00K $16.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $33.00K
YoY Change -96.33%
Total Long-Term Assets $568.0K $649.0K $0.00
YoY Change -35.16%
TOTAL ASSETS
Total Short-Term Assets $108.4M $115.3M $200.0K
Total Long-Term Assets $568.0K $649.0K $0.00
Total Assets $109.0M $115.9M $200.0K
YoY Change 93.73% 57874.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.028M $891.0K $100.0K
YoY Change -15.25% 791.0%
Accrued Expenses $352.0K $231.0K $1.000M
YoY Change -58.34% -76.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.444M $4.021M $1.200M
YoY Change 73.65% 235.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $185.0K $275.0K
YoY Change
Total Long-Term Liabilities $185.0K $275.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.444M $4.021M $1.200M
Total Long-Term Liabilities $185.0K $275.0K $0.00
Total Liabilities $5.629M $4.296M $1.200M
YoY Change 81.58% 258.0%
SHAREHOLDERS EQUITY
Retained Earnings -$42.20M -$33.40M
YoY Change 193.06%
Common Stock $145.7M $145.1M
YoY Change 1144.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $103.3M $111.7M -$943.0K
YoY Change
Total Liabilities & Shareholders Equity $109.0M $115.9M $200.0K
YoY Change 93.73% 57874.0%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$8.773M -$6.345M -$2.550M
YoY Change -13.22% 148.82%
Depreciation, Depletion And Amortization $1.000K
YoY Change
Cash From Operating Activities -$5.675M -$6.134M -$1.038M
YoY Change 288.7% 490.94%
INVESTING ACTIVITIES
Capital Expenditures -$3.000K -$13.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$3.437M -$9.251M
YoY Change
Cash From Investing Activities -$3.440M -$9.264M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -2.000K 924.0K
YoY Change -100.0% -100.22%
NET CHANGE
Cash From Operating Activities -5.675M -6.134M -1.038M
Cash From Investing Activities -3.440M -9.264M
Cash From Financing Activities 0.000 -2.000K 924.0K
Net Change In Cash -9.115M -15.40M -114.0K
YoY Change -116.54% 13408.77%
FREE CASH FLOW
Cash From Operating Activities -$5.675M -$6.134M -$1.038M
Capital Expenditures -$3.000K -$13.00K
Free Cash Flow -$5.672M -$6.121M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2021Q3 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1213000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
CY2020Q3 us-gaap Share Price
SharePrice
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
dei Entity Central Index Key
EntityCentralIndexKey
0001832168
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40192
dei Entity Registrant Name
EntityRegistrantName
Longboard Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-5009619
dei Entity Address Address Line1
EntityAddressAddressLine1
4275 Executive Square
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 950
dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
dei City Area Code
CityAreaCode
619
dei Local Phone Number
LocalPhoneNumber
592-9775
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
LBPH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17215350
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75461000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55316000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
37098000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2740000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
46000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
115299000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
55362000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
600000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16000
CY2021Q3 us-gaap Other Long Term Investments
OtherLongTermInvestments
33000
CY2021Q3 us-gaap Deferred Costs
DeferredCosts
0
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
876000
CY2021Q3 us-gaap Assets
Assets
115948000
CY2020Q4 us-gaap Assets
Assets
56238000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
891000
CY2021Q3 lbph Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1653000
CY2020Q4 lbph Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
916000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
231000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
845000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
918000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
161000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
328000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4021000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3135000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
275000
CY2020Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
55795000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10500000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13237500
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13237500
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3840540
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3840540
CY2021Q3 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
348450
CY2020Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
348450
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
145099000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
11708000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-24000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33424000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14400000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
111652000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2692000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115948000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56238000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4093000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1603000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13406000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2462000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2262000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
947000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5639000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1829000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6355000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2550000
us-gaap Operating Expenses
OperatingExpenses
19045000
us-gaap Operating Expenses
OperatingExpenses
4291000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6355000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2550000
us-gaap Net Income Loss
NetIncomeLoss
-4291000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4291000
us-gaap Profit Loss
ProfitLoss
-19024000
us-gaap Profit Loss
ProfitLoss
-4291000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19045000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4291000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
23000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
40000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-13000
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-19000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6345000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2550000
us-gaap Net Income Loss
NetIncomeLoss
-19024000
us-gaap Net Income Loss
NetIncomeLoss
-4291000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.41
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16866900
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3840540
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13538458
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3798025
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6345000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2550000
us-gaap Net Income Loss
NetIncomeLoss
-19024000
CY2021Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
10000
CY2020Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-24000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6335000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2550000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19048000
us-gaap Share Based Compensation
ShareBasedCompensation
1383000
us-gaap Share Based Compensation
ShareBasedCompensation
1148000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-142000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2727000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-322000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
122000
lbph Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-738000
lbph Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-716000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
22000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
148000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
756000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
84774000
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
8322000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76451000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2200000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
20145000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
217000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55316000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75461000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
217000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
CY2021Q1 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
On March 5, 2021, the Company filed an amendment to the Company’s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company’s common stock on a 1.38-for-1 basis (March Forward Stock Split). Adjustments corresponding to the March Forward Stock Split were made to the ratio at which the Company’s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March Forward Stock Split for all periods presented.
CY2021Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.38
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
2970000
CY2020Q4 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
On October 27, 2020, the Company filed an amendment to the Company’s certificate of incorporation to effect a forward stock split of shares of the Company’s common stock on a 2,783-for-1 basis (October Forward Stock Split). The par value of the common stock was not adjusted as a result of the October Forward Stock Split. The accompanying financial statements and notes to the financial statements give retroactive effect to the October Forward Stock Split for the periods presented.
CY2020Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
2783
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
175000
lbph Increase Decrease In Operating Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet
2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19030000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1983000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
37263000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37276000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2200000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000
CY2020 us-gaap Proceeds From Contributed Capital
ProceedsFromContributedCapital
3200000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33400000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-14400000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
112600000
CY2021Q3 us-gaap Foreclosed Assets
ForeclosedAssets
111300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.32%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.</span></p>
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4100000
CY2020Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
900000
us-gaap Property Plant And Equipment Basis Of Valuation
PropertyPlantAndEquipmentBasisOfValuation
Property and equipment are stated at cost
us-gaap Property Plant And Equipment Depreciation Methods
PropertyPlantAndEquipmentDepreciationMethods
straight-line basis
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13400000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1600000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2500000
CY2021Q3 lbph Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Three
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
23092000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37122000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1694687
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1694687
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
37098000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37122000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
24000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37098000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
14006000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
14006000
CY2021Q3 lbph Debt Securities Available For Sale Amortized Cost Maturity Allocated And Single Maturity Date After Year One Through Three
DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
23116000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37098000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
99000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
112000
CY2021Q3 lbph Accrued Recruitment Fees Current
AccruedRecruitmentFeesCurrent
71000
CY2020Q4 lbph Accrued Recruitment Fees Current
AccruedRecruitmentFeesCurrent
40000
CY2021Q3 lbph Accrued Computer Related Expenses
AccruedComputerRelatedExpenses
26000
CY2020Q4 lbph Accrued Computer Related Expenses
AccruedComputerRelatedExpenses
7000
CY2021Q3 lbph Accrued Legal And Accounting Fees Current
AccruedLegalAndAccountingFeesCurrent
19000
CY2020Q4 lbph Accrued Legal And Accounting Fees Current
AccruedLegalAndAccountingFeesCurrent
15000
CY2021Q3 lbph Accrued Financing Costs
AccruedFinancingCosts
0
CY2020Q4 lbph Accrued Financing Costs
AccruedFinancingCosts
639000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
231000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
845000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2692000
CY2021Q1 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
55795000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71849000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
333000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5699000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
119586000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4365000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
512000
CY2021Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-34000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6980000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
117449000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
538000
CY2021Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
10000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6345000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
111652000
CY2020Q1 us-gaap Partners Capital Account Contributions
PartnersCapitalAccountContributions
39000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
95000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-174000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-40000
CY2020Q2 us-gaap Partners Capital Account Contributions
PartnersCapitalAccountContributions
1237000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
555000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1567000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
185000
CY2020Q3 us-gaap Partners Capital Account Contributions
PartnersCapitalAccountContributions
924000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
498000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2550000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-943000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
873264
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
472973
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.47
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1346237
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
385406
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
36956
CY2021Q3 lbph Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Early Exercise Provision Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber
348450
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4800000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2100000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
200000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
200000
CY2021Q3 us-gaap Share Price
SharePrice
11.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0086
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7425
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.40
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
538000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
498000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1383000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1148000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2021Q2 lbph Area Of Office Space
AreaOfOfficeSpace
8681
lbph Effective Lease Date
EffectiveLeaseDate
2021-07-01
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-06-30
us-gaap Payments For Rent
PaymentsForRent
29000
CY2021Q2 lbph Percentage Of Increase In Rent
PercentageOfIncreaseInRent
0.045
CY2021Q2 us-gaap Security Deposit
SecurityDeposit
33000
lbph Payments For Rent Historical
PaymentsForRentHistorical
1000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
101000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
6000
us-gaap Operating Lease Payments
OperatingLeasePayments
91000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
679000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
600000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
328000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
275000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
603000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.090
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
90000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
370000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
189000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
649000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
46000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
603000
CY2020Q3 lbph Defined Contribution Plan Arena Matching Contributions
DefinedContributionPlanArenaMatchingContributions
3000000
lbph Defined Contribution Plan Arena Matching Contributions
DefinedContributionPlanArenaMatchingContributions
16000000
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2021Q3 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
34000000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
42000000

Files In Submission

Name View Source Status
0000950170-21-003093-index-headers.html Edgar Link pending
0000950170-21-003093-index.html Edgar Link pending
0000950170-21-003093.txt Edgar Link pending
0000950170-21-003093-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img7673250_0.jpg Edgar Link pending
lbph-20210930.htm Edgar Link pending
lbph-20210930.xsd Edgar Link pending
lbph-20210930_cal.xml Edgar Link unprocessable
lbph-20210930_def.xml Edgar Link unprocessable
lbph-20210930_htm.xml Edgar Link completed
lbph-20210930_lab.xml Edgar Link unprocessable
lbph-20210930_pre.xml Edgar Link unprocessable
lbph-ex31_1.htm Edgar Link pending
lbph-ex31_2.htm Edgar Link pending
lbph-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending